Apolipoprotein B: A Physiologic Argument for Its Use in Cardiovascular Disease Prevention

This editorial synthesizes the physiological case for ApoB as the fundamental driver of atherosclerosis — and by extension, the most appropriate primary target for cardiovascular prevention — rather than LDL-C, which measures cholesterol content of atherogenic particles rather than particle concentration itself.

The argument proceeds from basic mechanisms: atherosclerosis begins when ApoB-containing lipoproteins (LDL, Lp(a), IDL, VLDL remnants) enter the arterial wall and are retained by subendothelial proteoglycans. The probability of retention per unit time is proportional to particle concentration. ApoB provides a direct count of all atherogenic particles; LDL-C estimates the cholesterol content within one subset. When these two diverge — as they do in insulin resistance, high-triglyceride states, and metabolic syndrome — ApoB correctly identifies the higher arterial particle flux.

The three authors’ combination of clinical expertise (Sniderman), statistical modeling (Pencina), and genetic epidemiology (Thanassoulis) produces an editorial that is mechanistically rigorous and reflects the convergent evidence base. Though no new data are presented, the synthesis of physiological, statistical, and genetic arguments in a single editorial serves a synthesizing function in the field.

The argument has subsequently influenced guideline revisions and the evolving emphasis on ApoB measurement in international cardiology guidelines, particularly European guidelines (ESC/EAS 2019) which place ApoB as a primary risk marker.

We rate the evidence limited. An expert-synthesized editorial presenting the physiological foundation for ApoB as the primary cardiovascular risk marker — no new data, but a rigorous and influential articulation of the mechanistic case.